November 29, 2011

Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients

.   .   

There has been much interest in transplantation around eculizumab, a monoclonal antibody that blocks formation of the membrane attack complex of the complement cascade. In this single-centre, non-randomized study, patients with donor-specific antibody who were treated with eculizumab had a significantly lower rate of antibody-mediated rejection that a group of historical controls. There was also a lower rate of transplant glomerulopathy in the eculizumab-treated patients.

Related Articles:

Renal Transplantation

Comments are closed.